YKL-06-061 is primarily investigated for its potential in cancer research, particularly in targeting specific pathways involved in tumor growth and survival. It has shown promise in inhibiting certain kinases that play a critical role in cancer cell proliferation, making it a candidate for developing targeted cancer therapies. Researchers are exploring its efficacy in preclinical studies to understand its mechanism of action and potential for treating various malignancies. Additionally, YKL-06-061 is being studied for its ability to enhance the effectiveness of existing treatments when used in combination therapies. Its application extends to understanding cellular signaling pathways, which could provide insights into other diseases beyond cancer.